GHP Q2 2021

2 GHP / Q2 2021 Contents , Welcome to the 2021 Q2 edition of Global Health & Pharma Magazine, providing you with all the latest news and features from across the healthcare and pharmaceutical landscape. While the last eighteen months have seen all industries demonstrating resilience and versatility in a period defined by adversity, few have matched the exceptional work of the global healthcare and pharmaceutical industries. These impressive feats are by no means limited to successful vaccine programme rollouts or treatment of Covid-19 cases – as individuals have become more aware of the importance of caring for our general physical and mental wellbeing during the pandemic, organisations across the industry have seen demand for their products and services soar. That is certainly the case for the companies included in this quarter’s edition of GHP, including our cover company, BioMin Technologies, a leading researcher into dental sensitivity and developer of sensitivity relief and prevention products. We find out how this London-based start-up has grown since 2015 and plans to build on the momentum generated in online sales during the pandemic to see further growth that facilitates exciting advanced research into dental sensitivities. Join us as we explore many of the other success stories to come out of this vibrant and valued industry over the past few months. Until the next issue of GHP, we wish you all the best for the months ahead. Alex Abraham, Editor Website: AI Global Media, Ltd. (AI) takes reasonable measures to ensure the quality of the information on this web site. However, AI will not assume any legal liability or responsibility for the accuracy, correctness or completeness of any information that is available through this web site. If errors are brought to our attention, we will try to correct them. The information available through the website and our partner publications is for your general information and use and is not intended to address any particular finance or investment requirements. In particular, the information does not constitute any form of advice or recommendation by us or any of our partner publications and is not intended to be relied upon by users in making or refraining from making any investment or financial decisions. Appropriate independent advice should be obtained before making any such decision. Any arrangement made between you and any third party named in the site is at your sole risk and responsibility.